We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £211,595
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £270,543
Wombat is an investment platform that encourages millenials in the UK, Europe and beyond to invest in some of the world’s best-known brands for as little as £10. Their mission is to empower the generation of millenials to manage, save and grow money by breaking down barriers to traditional investing. The Wombat app was launched in the summer of 2019, and the company has already acquired more than 5,000 customers. Moreover, the company was nominated as Best Newcomer for the Robo Investing Awards and received positive press coverage. With the proceeds, Wombat is planning to build a strong customer base, fulfil growth strategy with a significant increase in marketing, product development, and to educate customers about investing.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £435,717
Cornish Lithium (CL) is a mineral exploration company engaged in the discovery of lithium and other battery metals in Cornwall. It intends to create a 'Battery Metals Hub' in the UK through its efforts. CL has received funding to build the first European Union (EU) pilot lithium extraction plant powered by geothermal waters. It asserts that some of the world's highest grades of lithium are found in geothermal waters. The company has also secured UK Government funding for a new lithium extraction pilot plant in Cornwall. CL has drilled 41 shallow boreholes in a former china clay pit near St Austell, demonstrating the potential to extract lithium from granite. The company will use the investment to accelerate the company towards commercial production of lithium.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £5,199,999
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £200,000
AdLaunch is an online video maker tool aimed at social media advertising creation. Using its patented AI-powered video generation technology, it enables businesses to create multiple high-quality videos, realtime previews and edit videos in the browser itself. This helps companies undertake online video advertising almost instantaneously within their respective budgets. AdLaunch has 11,000 users in over 130 countries worldwide. It has made 1.4 million pre-licensed HD videos and high-quality photos. The company aims to become synonymous with creating data-driven video ads and video campaigns. AdLaunch was awarded the 'Third Prize' at the Slush 100 pitch competition out of 2650 companies. it also secured three government R&D grants totaling £219,000 from the Business Finland - the Finnish Innovation Agency. AdLaunch is partnering with AppSumo which has a user base of 730,000 registered newsletter readers. With the proceeds, the company will develop its video generator and invest £8000 per month on Google, Facebook, and YouTube advertising to accelerate its customer acquisition.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £85,278
MedicSpot is a healthcare company that is aiming to revolutionise healthcare delivery by combining the advantages of online and offline care. The company provides patients at designated hospitals with diagnostic tools like a stethoscope, oximeter, blood pressure monitor and thermometer which, in turn, is connected to the MedicSpot network. Onboard General Physicians (GPs) engage in live sessions with patients, guide them on how to use the tools, and perform a variety of diagnoses like listening to a patient’s heart and lungs, looking down their throat and into their ears, taking their blood pressure and oxygen readings, and measuring their body temperature. The company is also expanding into another subsidiary, Arc Health, which it claims will perform the aforementioned tasks with more efficiency and accuracy. The company will use the investment to increase the number of Medicspot clinics to 1,000, gain further NHS market share, launch a corporate business model and allow international pilots to take place.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,048,396
B-North is creating an SME business bank that will deliver fast decisions with loans being given in two weeks. Its model is formed around strong relationships with both brokers and customers. B-North is in a positive conversation with the British Business Bank for Tier 2 debt, and its FinTech enabled lending platform is excellent. The funds will be used to expand the team and develop the platform. The company also aims at assembling a highly-experienced and ambitious management team supported by a heavyweight board.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £2,815,350
B-North intends to revolutionise the business lending industry, which is often outdated, impersonal and slow. The fintech company uses some of the most advanced cloud-based technology, coupled with face-to-face relationship teams to get the best lending solutions for borrowers and their businesses. The company is powered by a team with prior experience in starting and scaling challenger banks, and profitability is its focused goal. B-North has submitted the banking licence application, and the result is expected by 2020.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £2,135,456
Studio Pictures Limited is a UK based production company that specialises in the development of high-quality British film and TV projects. The company's interest predominantly lies within the British film and television industry that can be created within budget ranging from £1 million - £15 million. The company has established relationships with studio houses such as Warner Bros., Sony Pictures and Lionsgate and aims to build upon projects that can be made into a franchise. Their production, A Steet Cat Named Bob, went on to be distributed by Sony Pictures in the UK and had a Royal Premiere in London. Studio Pictures Limited will consider putting up to a maximum of 20% of the budget for each project as equity, on a case by case basis, subject to company reserves. With the proceeds, the company will grow and scale the business. It will become a tenant at Twickenham Studios in West London and look to profitable emerging markets, i.e. streaming, animation and interactive movies to become one of the leading UK production companies.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph